{"id":26920,"date":"2025-01-31T03:29:00","date_gmt":"2025-01-30T21:59:00","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/"},"modified":"2025-02-01T23:07:25","modified_gmt":"2025-02-01T17:37:25","slug":"adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/","title":{"rendered":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025"},"content":{"rendered":"

Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – January 30, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.<\/p>\n

Guggenheim Securities SMID Cap Biotech Conference, New York, NYFireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. ESTWebcast link: https:\/\/wsw.com\/webcast\/guggen2\/adap\/1969770<\/a><\/p>\n

This event can also be accessed by visiting ‘Events’, under the ‘News Center’ tab, in the ‘Investors & Media’ section of Adaptimmune’s website at www.adaptimmune.com<\/a>. Following the event, a replay of the presentation will be made available.<\/p>\n

About Adaptimmune
\nAdaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient’s cancer treatment experience.<\/p>\n

Forward-Looking Statements
\nThis release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.<\/p>\n

\n

Adaptimmune Contact
\nInvestor Relations
\nJuli P. Miller, Ph.D. – VP, Corporate Affairs and Investor Relations
\nT : +1 215 825 9310
\nM : +1 215 460 8920
\nJuli.Miller@adaptimmune.com<\/a><\/p>\n

Media Relations
\nDana Lynch, Senior Director of Corporate Communications
\nM: +1 267 990 1217
\nDana.Lynch@adaptimmune.com<\/a><\/p>\n<\/div>\n

Featured Article<\/p>\n","protected":false},"excerpt":{"rendered":"

Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – January 30, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[25849],"class_list":["post-26920","post","type-post","status-publish","format-standard","","category-international","tag-adaptimmune-therapeutics"],"yoast_head":"\nAdaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – January 30, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-30T21:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-01T17:37:25+00:00\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/\",\"name\":\"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2025-01-30T21:59:00+00:00\",\"dateModified\":\"2025-02-01T17:37:25+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/","og_locale":"en_US","og_type":"article","og_title":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Matribhumi Samachar English","og_description":"Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – January 30, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, …","og_url":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2025-01-30T21:59:00+00:00","article_modified_time":"2025-02-01T17:37:25+00:00","author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/","url":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/","name":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2025-01-30T21:59:00+00:00","dateModified":"2025-02-01T17:37:25+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/01\/31\/adaptimmune-to-participate-in-the-guggenheim-securities-smid-cap-biotech-conference-february-6-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/26920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=26920"}],"version-history":[{"count":1,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/26920\/revisions"}],"predecessor-version":[{"id":27115,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/26920\/revisions\/27115"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=26920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=26920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=26920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}